PMID- 20336593
OWN - NLM
STAT- MEDLINE
DCOM- 20100622
LR  - 20211020
IS  - 2040-3429 (Electronic)
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 11
IP  - 4
DP  - 2010 Apr
TI  - T1R and T2R receptors: the modulation of incretin hormones and potential targets 
      for the treatment of type 2 diabetes mellitus.
PG  - 447-54
AB  - Type 2 diabetes mellitus (T2DM), which is characterized by insulin and glucose 
      dysregulation, is a major contributor to the development of cardiovascular 
      disease, renal failure and premature death. Incretin hormones are released from 
      the intestines upon nutrient ingestion and contribute to glucose homeostasis in 
      part by promoting insulin secretion from the pancreas. Drugs that enhance the 
      incretin response have emerged as effective treatments for T2DM. Several recent 
      studies have revealed that incretin secretion from enteroendocrine cells in the 
      intestines can be modulated by T1R and T2R receptors, proteins that have been 
      demonstrated to function as taste receptors. This review focuses on the 
      intriguing finding that taste receptors may be involved in modulating the 
      incretin response, and considers T1Rs and T2Rs as potential targets for new 
      hypoglycemic drugs.
FAU - Dotson, Cedrick D
AU  - Dotson CD
AD  - University of Maryland School of Medicine, Department of Anatomy and 
      Neurobiology, Baltimore, MD 21201, USA.
FAU - Vigues, Stephan
AU  - Vigues S
FAU - Steinle, Nanette I
AU  - Steinle NI
FAU - Munger, Steven D
AU  - Munger SD
LA  - eng
GR  - R03 DC007317/DC/NIDCD NIH HHS/United States
GR  - DC010110/DC/NIDCD NIH HHS/United States
GR  - DK072488/DK/NIDDK NIH HHS/United States
GR  - R01 HL076768/HL/NHLBI NIH HHS/United States
GR  - HL076768/HL/NHLBI NIH HHS/United States
GR  - R01 DC010110/DC/NIDCD NIH HHS/United States
GR  - DC010763/DC/NIDCD NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - P30 DC010763/DC/NIDCD NIH HHS/United States
GR  - DC007317/DC/NIDCD NIH HHS/United States
GR  - R01 DC005786/DC/NIDCD NIH HHS/United States
GR  - R01 DC010110-01A1/DC/NIDCD NIH HHS/United States
GR  - DC005786/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (taste receptors, type 2)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Glucose/metabolism/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Receptors, G-Protein-Coupled/*metabolism
PMC - PMC4535793
MID - NIHMS713933
COIS- Disclosure The authors have previously collaborated with researchers at Senomyx, 
      Inc. but have no financial or other interests with the company.
EDAT- 2010/03/26 06:00
MHDA- 2010/06/23 06:00
PMCR- 2015/08/13
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/06/23 06:00 [medline]
PHST- 2015/08/13 00:00 [pmc-release]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2010 Apr;11(4):447-54.